Clinical trials: Hemostatic Agents
Multiple Myeloma and Plasma Cell Neoplasm, Neurotoxicity
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
RATIONALE: Bortezomib and thalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Bortezomib may also stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00792142
- Testing
- bortezomib, dexamethasone, melphalan
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- City of Hope Medical Center
Hematologic Neoplasms, Leukemia
Musculoskeletal Ultrasound in Patients With Hematologic Malignancies
This study evaluates the role and diagnostic value of musculoskeletal ultrasonography (MSUS) in adult patients with hematologic malignancies who present with musculoskeletal symptoms.
- Conditions
- Hematologic Neoplasms, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT07785505
- Volunteers
- 50 people
- Sponsor
- Assiut University
Multiple Myeloma
A Open-Label Phase in Participants With Multiple Myeloma
This is an open-label, multi-center phase II study of IBI3003 in combination with anti-CD38 monoclonal antibody in adult subjects with multiple myeloma.
- Trial name
- NCT07764861
- Testing
- Dexamethasone, IBI3003, Lenalidomide
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Multiple Myeloma
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
Based on the pre-clinical data the investigators hypothesize that G-CSF treatment in patients with multiple myeloma will generate a 'hostile' bone marrow microenvironment for myeloma cells, depriving them of key support signals…
- Trial name
- NCT01537861
- Testing
- Filgrastim, Bortezomib, Carfilzomib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma
Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma
Primary Objective: To evaluate the pharmacokinetics (PK) of isatuximab. Secondary Objectives: To evaluate the safety and tolerability of isatuximab. To assess the preliminary antitumor effect of isatuximab.
- Trial name
- NCT03733717
- Testing
- Isatuximab SAR650984
- Where
- 3 sites in China
- Volunteers
- 25 people
- Sponsor
- Sanofi
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
Selinexor, a first-in-class, oral selective exportin 1 (XPO1) inhibitor, has shown promise in pre-clinical and clinical studies.
- Trial name
- KPT-IST-391 (NCT06225310)
- Testing
- Selinexor, Ruxolitinib, Methylprednisolone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oncotherapeutics
Coagulopathy, Congenital Heart Disease
FFP Usage in Pediatric CV Surgery
When small children undergo heart surgery with the heart-lung machine, in the past, blood products to help the blood clot such as Fresh Frozen Plasma (FFP) was routinely used in children under 10kg.
- Trial name
- NCT05819788
- Where
- Canada
- Volunteers
- 431 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Chronic Lymphocytic Leukemia, Multiple Myeloma
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
A phase 1, first-in-human trial to evaluate the safety and tolerability of LAVA-051 in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), or Acute Myeloid Leukemia (AML).
- Conditions
- Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
- Trial name
- NCT04887259
- Testing
- LAVA-051, Interleukin 2
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 16 people
- Sponsor
- Lava Therapeutics
Multiple Myeloma
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
The purpose of this study is to determine if the addition of daratumumab to velcade (bortezomib) melphalan-prednisone (VMP) will prolong progression-free survival (PFS) compared with VMP alone in participants with previously…
- Trial name
- NCT02195479
- Testing
- Velcade, Melphalan, Prednisone
- Where
- 160 sites in United States, Argentina and 22 more
- Volunteers
- 706 people
- Sponsor
- Janssen Research & Development, LLC
Cardiac Disease, Multiple Myeloma
Detection and Pathogenesis of Novel Protein F
From December 6, 2019 to March 23, 2020, the research group of Qingkun Fan found a novel protein(temporarily named protein F) in heparin anticoagulant plasma of three patients with heart disease.
- Trial name
- NCT04338386
- Volunteers
- 100 people
- Sponsor
- Wuhan Asia Heart Hospital
Thrombosis, Multiple Myeloma
Prevalence of Asymptomatic Thrombosis in Multiple Myeloma
Malignant hemopathies, such as solid cancers, increase the risk of venous and arterial thromboembolic events. The incidence of symptomatic venous thromboembolic events is particularly high in myeloma, linked to the usual risk…
- Trial name
- NCT03145870
- Testing
- Echoing of the lower limbs and measuring the systolic pressure index
- Where
- France
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Multiple Myeloma
Chemotherapy and G-CSF for Mobilization
This study aims to demonstrate that the mobilization with cytokine stimulation with G-CSF alone is non-inferior as compared to the standard mobilization with chemotherapy and G-CSF while associated with fewer side effects in…
- Trial name
- MOCCCA (NCT03442673)
- Testing
- Vinorelbine, Gemcitabine, G-CSF
- Where
- Switzerland
- Volunteers
- 137 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Leukemia, Lymphoma
Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00044954
- Testing
- therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate
- Where
- 14 sites in United States
- Sponsor
- University of Texas Southwestern Medical Center
COVID-19, SARS-CoV-2 Infection
Coagulopathy and Vasculopathy Assessment as a Predictor of the Severity of SARS-CoV-2 / COVID-19 Infection
On 30 January 2020, WHO declared the SARS-CoV-2 outbreak as a public health emergency of international concern. Compared to SARS-CoV, which caused an outbreak of SARS in 2003, SARS-CoV-2 has a higher transmission capacity.
- Trial name
- SARCODO (NCT04624997)
- Testing
- biological sample
- Where
- 2 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Myeloma
PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma
This is a qualitative (interview) study to explore the experiences of people receiving treatment for MM and to understand what matters most to participants when making treatment decisions.
- Trial name
- iPREFER (NCT06322927)
- Testing
- Patient Interview
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- The Christie NHS Foundation Trust
Multiple Myeloma
BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma
This was a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor…
- Trial name
- NCT04318327
- Testing
- PHE885
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 96 people
- Sponsor
- Novartis Pharmaceuticals
Sickle Cell Disease
Study of Biological Markers in Children With Sickle Cell Disease
Sickle cell disease is associated with significant morbi-mortality hence the interest in an early and targeted care. At present, there is no plasmatic marker able to identify infants at higher risk of developping severe…
- Trial name
- NCT04839159
- Testing
- Blood sampling
- Where
- 3 sites in Belgium
- Volunteers
- 41 people
- Sponsor
- Queen Fabiola Children's University Hospital
Waldenstrom Macroglobulinemia
Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia
In Waldenström macroglobulinemia (WM) chemotherapy induces only low CR/VGPR (Complete Remission/ Very Good Partial Response) rates and responses of short duration compared to other indolent lymphomas.
- Trial name
- CZAR-1 (NCT04263480)
- Testing
- Carfilzomib + Ibrutinib, Ibrutinib
- Where
- 17 sites in Austria, Germany and 1 more
- Volunteers
- 99 people
- Sponsor
- Christian Buske
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
Drugs used in chemotherapy, such as FAU, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00769288
- Testing
- 2'-F-ara-deoxyuridine, positron emission tomography, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Bivalirudin in Elderly Patients Undergoing Elective Percutaneous Coronary Intervention.
The study is an investigator-sponsored, prospective, multicenter, randomized, open-label study designed to compare efficacy and safety between bivalirudin and heparin in elderly patients with acute coronary syndrome undergoing…
- Conditions
- Acute Coronary Syndrome, Percutaneous Coronary Intervention, Aging, Anticoagulants and Bleeding Disorders
- Trial name
- NCT04046029
- Testing
- Bivalirudin, Heparin
- Where
- China
- Volunteers
- 240 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.